Hiroshige et al. (1996) [51] |
6-month prospective |
Prevalent 8 NIPD, 5 CCPD, 5 CAPD |
Yes |
Rate of change of RRF in −0.29 (NIPD) versus −0.34 (CCPD) versus +0.01 (CAPD) mL/min/month |
Rodriguez et al. (1998) [56] |
3-year prospective |
Prevalent 25 CAPD, 20 APD |
No |
|
Hufnagel et al. (1999) [52] |
18-month prospective |
Incident 6 NIPD, 12 CCPD, 18 CAPD |
Yes |
Rate of change of RRF in −0.26 (APD) versus −0.13 (CAPD) mL/min/month |
Bro et al. (1999) [57] |
6-month randomized controlled trial |
Prevalent 13 CAPD, 12 APD |
No |
|
Moist et al. (2000) [28] |
3-year retrospective |
Incident 722 CAPD, 310 APD |
No |
|
De Fijter et al. (2000) [53] |
2-year randomized controlled trial |
Incident 13 CCPD, 11 CAPD |
No |
|
Gallar et al. (2000) [58] |
1-year prospective |
Incident 11 CAPD, 9 APD |
No |
|
Singhal et al. (2000) [59] |
4-year prospective |
Incident 211 CAPD, 31 APD |
No |
|
Holley et al. (2001) [60] |
9-year retrospective |
Incident 11 CAPD, 9 APD |
No |
|
Jansen et al. (2002) [39] |
1-year prospective |
Incident 243 PD subjects |
No |
|
Hidaka et al. (2003) [61] |
6-year prospective |
Incident 27 CAPD, 7 APD |
Yes |
Approximate time to decrease 50% of RRF in CAPD is 15 months versus APD 4 months, P < 0.001 |
Johnson et al. (2003) [36] |
6-year prospective |
Incident 134 CAPD, 12 APD |
No |
|
Rodriguez-Carmona (2004) [62] |
1-year prospective |
Incident 53 CAPD, 51 APD |
Yes |
Hazard ratio of APD versus CAPD = −1.2 (−2.25 to −0.15, P = 0.02) |
Rabindranath (2007) [63] |
Systematic review of 3 RCT |
49 PD subjects |
No |
|
Liao (2009) [27] |
10-year retrospective |
Incident 188 CAPD, 82 APD |
No |
|
Su et al. (2010) [64] |
9-year retrospective |
Prevalent 140 CAPD, 32 APD |
No |
|
Cnossen et al. (2010) [55] |
7-year retrospective |
Incident 179 CAPD, 441 APD |
No |
|
Balasubramanian et al. (2011) [54] |
5-year retrospective |
Incident 178 CAPD, 13 APD |
No |
|
Michels et al. (2011) [65] |
3-year retrospective |
Incident 505 CAPD, 78 APD |
Yes |
Higher risk of loss of RRF in APD compared to CAPD in first year of treatment (adjusted hazard ratio 2.66, CI 1.66–4.44) |